BioNTech
platform strategy technology agnostic innovation engine | BioNTech
Company
Deck Type
Sector
Industry
Deck date
June 2022
Slide
28 of 156
Related slides by other companies
Genprex
Investor Presentation
November 2024
program highlights | Genprex
Enochian Biosciences
Investor Presentation
January 2024
cell and gene platforms engineered dendritic cell therapeutic vaccine solid tumors engineered cell therapeutic vaccine | Enochian Biosciences
Codiak
IPO
October 2020
a precision engineered vaccine platform | Codiak
Alkermes
Investor Day
March 2021
therapy has proven anti tumor efficacy is a natural regulator of the activity of lymphocytes involved in the immune response human as can drive complete and durable responses in certain tumor types but its toxicity profile significantly limits its potential application a molecule with differentiated tolerability that targets the pathway could be complementary to a wide range of other therapeutic approaches non specific agents specific agents cytotoxic chemotherapy first generation native scientific insight enabled by targeted agents engineered new molecule with engineered specificity | Alkermes
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Results
March 2022
Investor Day
February 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights